Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
14 October 2021 - 9:32PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of October 2021
Commission File Number: 001-37643
PURPLE BIOTECH LTD.
(Translation of registrant’s name into English)
4 Oppenheimer Street, Science Park, Rehovot
7670104, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the Registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the Registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Settlement Agreement
Purple
Biotech Ltd. (the “Registrant” or the “Company”) is announcing that the Company
entered into a settlement agreement with Lupin Ltd. and its subsidiary Lupin Pharmaceuticals, Inc. (collectively, “Lupin”),
resolving the Company’s patent litigation against Lupin. The litigation concerned Lupin’s filing of an Abbreviated New Drug
Application (ANDA) seeking approval from the U.S. Food and Drug Administration (FDA) to market a generic version of the Company’s
commercial drug CONSENSI®. This agreement with Lupin allows Lupin to enter the market on March 1, 2030 and earlier, under certain
circumstances.
Incorporation by Reference
This Form 6-K, is hereby
incorporated by reference into each of the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 20, 2016 (Registration file number
333-211478), the Registrant’s Registration Statement on Form S-8 filed with the Securities
and Exchange Commission on June 6, 2017 (Registration file number 333-218538), the Registrant’s Registration Statement on Form F-3, as amended, originally filed with the Securities and Exchange Commission on July 16, 2018
(Registration file number 333-226195), the Registrant’s Registration Statement on Form S-8 filed
with the Securities and Exchange Commission on March 28, 2019 (Registration file number 333-230584), the Registrant’s Registration
Statement on Form F-3 filed with the Securities and Exchange Commission on September 16,
2019 (Registration file number 333-233795), the Registrant’s Registration Statement on Form F-3 filed
with the Securities and Exchange Commission on December 2, 2019 (Registration file number 333-235327), the Registrant’s Registration
Statement on Form F-3 filed with the Securities and Exchange Commission on May 13, 2020
(Registration file number 333- 238229), the Registrant’s Registration Statement on Form S-8 filed
with the Securities and Exchange Commission on May 28, 2020 (Registration file number 333-238481) and each of the Registrant’s Registration
Statements on Form F-3 filed with the Securities and Exchange Commission on July 10, 2020 (Registration file numbers 333-239807 and 333-233793),
to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently
filed or furnished.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
October 14, 2021
|
PURPLE BIOTECH LTD.
|
|
|
|
|
By:
|
/s/ Isaac Israel
|
|
|
Isaac Israel
|
|
|
Chief Executive Officer
|
2
Kitov Pharma (NASDAQ:KTOVW)
Historical Stock Chart
From Sep 2024 to Oct 2024
Kitov Pharma (NASDAQ:KTOVW)
Historical Stock Chart
From Oct 2023 to Oct 2024